Tazemetostat Hydrobromide Drug Due Diligence Report 2026

This Tazemetostat Hydrobromide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Tazemetostat Hydrobromide can convert its Small molecule drug profile and EZH2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Tazemetostat Hydrobromide (query alias: tazemetostat)
Modality / target	Small molecule drug; EZH2; EZH2 inhibitors, Epigenetic drug
Highest global status	Approved
Originator	Epizyme, Inc.
Active developers	Epizyme, Inc., Northwestern University, Ipsen SA

The MCP disease footprint includes Follicular Lymphoma, Sarcoma, Refractory Follicular Lymphoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06575686	Phase 2	Suspended	33	Incidence of unacceptable adverse events (Safety lead-in)
NCT06692452	Phase 2	Withdrawn	Not disclosed	Complete Response Rate (CRR)
NCT07407283	Phase 1/2	Recruiting	100	Recommended Phase 2 Dose (RP2D) of SHR-4394 combined with anti-tumor therapy in prostate cancer participants

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Immune priming with the EZH2 inhibitor tazemetostat in B-cell lymphomas receiving CAR T-cell therapy.

Phase 1; n=13; evaluation: Positive. Reported fields: CR(in CR) = 77.0 %

Real-world evidence of tazemetostat in epithelioid sarcoma patients.

Not Applicable; n=19; evaluation: Positive. Reported fields: -; -; mOS = 17.18 month ( 4.24 - NE)

Efficacy and safety results of tazemetostat in Japanese patients with advanced epithelioid sarcoma: The phase 2 TAZETTA trial (NCCH2107).

Phase 2; n=17; evaluation: Positive. Reported fields: PFS(18-week) = 31.3 % ( 14.0 - 50.2)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Tazemetostat Hydrobromide addresses Follicular Lymphoma, Sarcoma, Refractory Follicular Lymphoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2022-06-27	Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology	Approved	US$247.0M stated total
2021-08-07	HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China	Approved	US$25.0M upfront; US$350.0M milestones; US$375.0M stated total
2019-11-05	Royalty Pharma acquires Eisai's royalties on global sales of tazemetostat for cancer treatment.	NDA/BLA	US$110.0M upfront; US$220.0M milestones; US$330.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Application of EZH2 inhibitor and JAK inhibitor in preparation of medicine for treating tumors”. The milestone feed surfaced a patent-application signal described as “Synthesis method of Tazemetostat”. The milestone feed surfaced a patent-application signal described as “COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH EZH1 and/or EZH2 INHIBITOR”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO